GleamWall
中文EN

VYCO VYCOR MEDICAL INC

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1424768 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-10.2%
TTM net income YoY-289.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR6.3%
Net income 3-yr CAGR—

Margins

Gross margin82.4%
Operating margin2.5%
Net margin-3.8%
FCF margin—
EBITDA margin6.0%

Returns

ROE—
ROA-6.7%
ROIC (approx.)—
Asset turnover1.79x

Leverage & solvency

Liabilities / assets557.3%
Debt / equity—
Current ratio0.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.18x
Accruals ratio-21.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$414,895$418,264$458,540$416,877$513,792$496,353$436,378$455,226
Cost of revenue$61,878$73,819$83,387$81,507$61,860$81,082$77,844$57,844
Gross profit$353,017$344,445$375,153$335,370$451,932$415,271$358,534$397,382
R&D expense———$0$0$4,201$5,762$6,637
SG&A expense$310,713$322,711$315,365$357,015$404,967$345,043$350,698$356,521
Operating income$27,424$6,851$45,808-$36,525$32,085$51,146-$12,806$19,344
Pretax income$1,521-$19,109$20,095-$62,379$4,990$25,713-$38,514-$6,685
Net income$738-$22,288$20,108-$62,686$4,936$23,887-$38,563-$6,737
EBITDA$42,304$21,734$59,788-$21,645$46,965$66,027$2,074$34,224
EPS (basic)0.000.000.00—0.000.00-0.01—
EPS (diluted)0.000.000.00—0.000.00-0.01—
Weighted avg. shares (diluted)33.37M33.37M33.37M—33.37M38.67M33.37M—
Balance sheet
Cash & equivalents$199,409$158,907$173,634$86,982$64,230$99,700$61,049$105,648
Receivables$185,617$202,447$194,041$218,891$326,052$202,669$229,411$245,260
Inventory$165,291$190,508$181,910$159,202$167,415$156,033$176,373$146,084
Current assets$653,489$635,877$651,047$563,422$662,596$554,355$600,695$619,614
PP&E, net$87,326$101,373$116,128$133,936$148,474$164,338$176,585$192,693
Total assets$964,879$813,174$854,071$830,420$941,195$878,946$940,831$998,117
Current liabilities$5.11M$4.93M$4.95M$4.78M$4.82M$4.58M$4.65M$4.50M
Total liabilities$5.38M$5.06M$5.08M$4.92M$4.97M$4.75M$4.83M$4.69M
Shareholders' equity-$4.41M-$4.25M-$4.23M-$4.09M-$4.02M-$3.87M-$3.89M-$3.69M
Shares outstanding33.37M33.37M33.37M33.37M33.37M33.37M33.37M33.37M
Cash flow statement
Operating cash flow$5,886-$4,843$99,422$39,232-$72,427$46,633-$26,909-$38,281
Capital expenditure———$1,605$1——-$2
Free cash flow———$37,627-$72,428——-$38,279
Investing cash flow-$1,540$342$2,140-$1,606$0——$170
Financing cash flow$36,156-$10,246-$14,910-$14,874$36,957-$5,205-$17,690-$13,874
Depreciation & amortization$14,880$14,883$13,980$14,880$14,880$14,881$14,880$14,880
Stock-based compensation———$0$12,209$0$18,315$18,314

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.